Marathon Capital Management increased its stake in Enzo Biochem Inc (ENZ) by 119.33% based on its latest 2017Q3 regulatory filing with the SEC. Marathon Capital Management bought 137,225 shares as the company’s stock rose 31.87% with the market. The institutional investor held 252,225 shares of the health care company at the end of 2017Q3, valued at $2.64 million, up from 115,000 at the end of the previous reported quarter. Marathon Capital Management who had been investing in Enzo Biochem Inc for a number of months, seems to be bullish on the $315.81 million market cap company. The stock decreased 1.90% or $0.13 during the last trading session, reaching $6.73. About 106,128 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since February 13, 2017 and is uptrending. It has outperformed by 27.62% the S&P500.
John Burbank decreased its stake in Jd Com Inc (JD) by 49.25% based on its latest 2017Q3 regulatory filing with the SEC. Passport Capital Llc sold 142,577 shares as the company’s stock rose 37.55% with the market. The hedge fund run by John Burbank held 146,897 shares of the consumer services company at the end of 2017Q3, valued at $5.61 million, down from 289,474 at the end of the previous reported quarter. Passport Capital Llc who had been investing in Jd Com Inc for a number of months, seems to be less bullish one the $62.26 billion market cap company. The stock increased 1.84% or $0.79 during the last trading session, reaching $43.72. About 11.48 million shares traded. JD.com, Inc. (NASDAQ:JD) has risen 77.67% since February 13, 2017 and is uptrending. It has outperformed by 60.97% the S&P500.
Among 21 analysts covering JD.com (NASDAQ:JD), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. JD.com had 45 analyst reports since August 4, 2015 according to SRatingsIntel. UBS upgraded JD.com, Inc. (NASDAQ:JD) on Monday, October 30 to “Buy” rating. As per Wednesday, January 11, the company rating was initiated by Bernstein. On Tuesday, August 4 the stock rating was initiated by TH Capital with “Buy”. Goldman Sachs initiated JD.com, Inc. (NASDAQ:JD) on Friday, November 6 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, December 13 report. On Tuesday, October 3 the stock rating was maintained by Jefferies with “Buy”. JP Morgan maintained JD.com, Inc. (NASDAQ:JD) rating on Wednesday, November 15. JP Morgan has “Overweight” rating and $50 target. The stock of JD.com, Inc. (NASDAQ:JD) earned “Buy” rating by KeyBanc Capital Markets on Thursday, January 25. The company was maintained on Tuesday, November 14 by Wells Fargo. The firm has “Buy” rating given on Monday, November 13 by KeyBanc Capital Markets.
Passport Capital Llc, which manages about $4.54 billion and $362.25M US Long portfolio, upped its stake in Broadcom Ltd by 4,420 shares to 25,043 shares, valued at $6.07M in 2017Q3, according to the filing. It also increased its holding in Hsn Inc (NASDAQ:HSNI) by 199,810 shares in the quarter, for a total of 325,000 shares, and has risen its stake in Unitedhealth Group Inc (NYSE:UNH).
Analysts await JD.com, Inc. (NASDAQ:JD) to report earnings on March, 1. They expect $-0.03 EPS, up 83.33% or $0.15 from last year’s $-0.18 per share. After $0.10 actual EPS reported by JD.com, Inc. for the previous quarter, Wall Street now forecasts -130.00% negative EPS growth.
Since October 25, 2017, it had 0 insider buys, and 5 insider sales for $1.71 million activity. Shares for $235,062 were sold by O’Brien James Michael. WEINER BARRY W sold 54,126 shares worth $547,214.
Marathon Capital Management, which manages about $237.50 million US Long portfolio, decreased its stake in Tower Semiconductor Newf (NASDAQ:TSEM) by 17,985 shares to 139,565 shares, valued at $4.29 million in 2017Q3, according to the filing. It also reduced its holding in Gladstone Land Corp (NASDAQ:LAND) by 29,800 shares in the quarter, leaving it with 151,390 shares, and cut its stake in Hudson Technologies Inc (NASDAQ:HDSN).
Investors sentiment decreased to 1.24 in Q3 2017. Its down 0.35, from 1.59 in 2017Q2. It turned negative, as 18 investors sold ENZ shares while 28 reduced holdings. 23 funds opened positions while 34 raised stakes. 25.84 million shares or 2.45% more from 25.22 million shares in 2017Q2 were reported. Price T Rowe Assoc Inc Md has 13,209 shares. Bogle Inv Management Ltd Partnership De has 0.08% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 114,790 shares. City Company has invested 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Dupont Mngmt has 26,710 shares. Berson & Corrado Invest Advsr Limited Company accumulated 238,726 shares. Hudock Grp Incorporated Ltd Limited Liability Company, a Pennsylvania-based fund reported 242 shares. Prudential Fin has 86,300 shares for 0% of their portfolio. Invesco Ltd holds 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 152,976 shares. Citigroup invested in 11,141 shares. Bancorp Of New York Mellon holds 231,653 shares or 0% of its portfolio. Kopp Investment Advisors Lc has 165,727 shares. Strs Ohio stated it has 0% in Enzo Biochem, Inc. (NYSE:ENZ). 1.89M are held by Vanguard Incorporated. Cypress Lc (Wy) reported 275 shares stake. 20,000 were accumulated by Brookstone Mngmt.